Related references
Note: Only part of the references are listed.Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)
Brendan M. Everett et al.
CIRCULATION (2010)
Effect of Fluvastatin on Cardiac Outcomes in Kidney Transplant Patients With Systemic Lupus Erythematosus A Randomized Placebo-Controlled Study
Gudrun E. Norby et al.
ARTHRITIS AND RHEUMATISM (2009)
Update on statin-mediated anti-inflammatory activities in atherosclerosis
Fabrizio Montecucco et al.
SEMINARS IN IMMUNOPATHOLOGY (2009)
Immunomodulatory and Anti-Inflammatory Activities of Statins
Emilia Mira et al.
Endocrine Metabolic & Immune Disorders-Drug Targets (2009)
Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus
Kareem L. Graham et al.
ARTHRITIS AND RHEUMATISM (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus
Mary J. Roman et al.
ARTHRITIS AND RHEUMATISM (2007)
Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial
G. A. Ferreira et al.
RHEUMATOLOGY (2007)
A pravastatin dose-escalation study in systemic lupus erythematosus
Karen H. Costenbader et al.
RHEUMATOLOGY INTERNATIONAL (2007)
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis - The METEOR trial
John R. Crouse et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus
Elizabeth C. Jury et al.
JOURNAL OF IMMUNOLOGY (2006)
Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis a murine lupus model
Tamar Aprahamian et al.
JOURNAL OF IMMUNOLOGY (2006)
Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial
David A. Morrow et al.
CIRCULATION (2006)
Low-density lipoprotein-lowering medication and platelet function
Patrizia Ferroni et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2006)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
C-reactive protein levels and outcomes after statin therapy
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice
S Lawman et al.
JOURNAL OF IMMUNOLOGY (2004)
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis
A Yilmaz et al.
ATHEROSCLEROSIS (2004)
Premature coronary-artery atherosclerosis in systemic lupus erythematosus
Y Asanuma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus
MJ Roman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus
CY Ho et al.
RHEUMATOLOGY (2003)
Share Paper
